Endocrine Board Review 2025 Virtual Meeting
Endocrine Board Review 2025 Virtual Meeting
Availability
Expires on Dec 31, 2026
2 Courses
Cost
Member: $704.00
Non-Member: $849.00
In-Training Member: $574.00
Resident Member: $574.00
Resident Non-Member: $849.00
Credit Offered
64 AMA PRA Category 1 Credits
64 ABIM-MOC Points
64 Participation Credits
  • How to submit comments and questions for each exam question
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended
As you progress through each question in the Learning Mode version of the practice exam, select the available Comment icon in the top right corner to submit your question/feedback. 


During the live Q&A session, you will also have the opportunity to submit questions for the faculty through the Q&A function. You may "upvote" similar or other interesting questions you see submitted to boost its ranking in the queue and the likelihood it will be addressed by faculty during the live session. 

Endocrine Board Review (EBR) is a board examination preparation course designed both for endocrine fellows who have completed or are nearing completion of their fellowship and are preparing to sit the board certification exam, and for practicing endocrinologists in search of a comprehensive self-assessment of endocrinology, either to prepare for recertification or to update their practice. EBR 2025 consists of 221 case-based, American Board of Internal Medicine (ABIM)-style multiple-choice questions, presented in a mock exam format. Each section follows the ABIM’s Endocrinology, Diabetes, and Metabolism Certification Examination blueprint, covering the breadth and depth of the certification and recertification examinations. Each case is discussed comprehensively with detailed answer explanations and references. A customized score report is provided to all participants. Your registration provides access to the following components:

  • Endocrine Board Review 17th Edition—printed self-study book containing all 221 case-based questions and complete answer rationale.
  •  Interactive Practice Exam— Access 221 questions to evaluate your knowledge in key topical areas to enhance your ability to make appropriate diagnoses. This practice exam allows the learner to create their own test based on topical area, with options to adjust length of time, and measure confidence level in responses. You can submit questions for our faculty to address during the live Q&A sessions based on specific case questions.
    • Learning Mode: Answer 221 questions and receive immediate feedback and view the detailed answer rationale. This mode must be completed with a passing score of 70% in order to earn CME and MOC. You will be given unlimited attempts to obtain this score.
    • Mock Exam Mode: Perfect for simulating an exam. Retake this mock exam as often as you like and each time the questions will be re-organized. Feedback will be provided after completion of the exam.
      • Build your own exam: Within Mock Exam Mode, you have the option to create your own exams by choosing the topic(s) to be included and even set a timer.
  • Live Topical Q&A Sessions—taking place September 5-7, the live topical Q&A sessions offer the unique opportunity to engage with our expert faculty and ask challenging questions. In addition to being able to participate live, you will be able access the recordings of the Q&A sessions.
This activity is intended for endocrine fellows planning for initial certification, practicing endocrinologists preparing for an MOC assessment, or physicians seeking an in-depth review of endocrinology. The secondary target audience includes advanced practice nurses and physician assistants.

Upon completion of this educational activity, learners will be able to:

  • Demonstrate enhanced medical knowledge and clinical skills across all major areas of endocrinology.
  • Apply knowledge and skills in diagnosing, managing, and treating a wide spectrum of endocrine disorders.
  • Successfully complete the board examination for certification or recertification in the subspecialty of endocrinology, diabetes, and metabolism.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates the Endocrine Board Review 2025 17th Edition for a maximum of 55 AMA PRA Category 1 Credits and 55 points in the ABIM Maintenance of Certification (MOC) program. The Endocrine Society designates the Endocrine Board Review 2025 Live Q&A sessions for a maximum of 9 AMA PRA Category 1 Credits™ and 9 points in the ABIM Maintenance of Certification (MOC) program. 

Successful completion of this CME activity includes participation in the activity evaluation.  After completing the activity evaluation, participants will be able to save or print a CME certificate. The CME activity provider is responsible for submitting participant completion information to the ACCME to grant ABIM MOC points.
 

CME credits and/or MOC points for the Endocrine Board Review 2025 17th Edition activity related to this material must be claimed by December 31, 2026. 

CME credits and/or MOC points for the Endocrine Board Review 2025 Live Q&A sessions activity related to this material must be claimed by December 31, 2025.

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in the Endocrine Board Review 2025 17th Edition for a maximum of 55 AMA PRA Category 1 Credits™ and designates the Endocrine Board Review 2025 Live Q&A sessions for a maximum of 9 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC)
Successful completion of each CME activity in the Endocrine Board Review 2025 17th Editioncourse, which includes participation in the evaluation component, enables the participant to earn up to 55 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Successful completion of each CME activity in the Endocrine Board Review 2025 Live Q&A sessions course, which includes participation in the evaluation component, enables the participant to earn up to 9 points in the ABIM Maintenance of Certification (MOC) program

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

Stephanie T. Page, MD, PhD -  Interim Program Chair
Professor/Head, Division of Metabolism, Endocrinology, and Nutrition
Co-Director, UW Medicine Diabetes Institute
Robert B. McMillen Professor of Medicine in Lipid Research
University of Washington School of Medicine

Kanishka Desai, MD
Clinical Associate Professor, Medicine - Endocrinology, Gerontology, & Metabolism
Stanford University

John D. Carmichael, MD
Clinical Chief
Division of Endocrinology, Diabetes, and Metabolism
Co-Director, USC Pituitary Center
Associate Professor of Clinical Medicine
Keck School of Medicine of the University of Southern California

Hans K. Ghayee, DO
Professor of Medicine
University of Florida
Faculty Member
North Florida/South Georgia
VA Medical Center

Sangeeta R. Kashyap, MD
Assistant Chief of Clinical Affairs
Division of Endocrinology, Diabetes and Metabolism
Weill Cornell Medicine New York Presbyterian

E. Michael Lewiecki, MD
Director of New Mexico Clinical
Research and Osteoporosis Center
Director of Bone Health ECHO
University of New Mexico
Health Sciences Center

Margaret Flynn Lippincott, MD
Assistant Professor of Medicine
Harvard Medical School
Physician Investigator
Reproductive Endocrine Unit
Massachusetts General Hospital

Elizabeth McAninch, MD
Clinical Associate Professor
Stanford University Medicine Center

Marie E. McDonnell, MD
Chief, Diabetes Section
Division of Endocrinology Diabetes and Hypertension
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School

Anne L. Peters, MD
Professor of Clinical Medicine
Keck School of Medicine of the University of Southern California

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Anne L. Peters, MD, has served as an advisory board member for Abbott Diabetes Care, Medscape, Novo Nordisk, Vertex, and Zealand and as a consultant for Blue Circle Health. She has received research support from Dexcom, Insulet, and Abbott Diabetes Care. She has stock options in Omada Health and Teladoc.

E. Michael Lewiecki, MD, has received Institutional research grants from Amgen, Radius, Ultragenyx, and Angitia, has served as a consultant for Amgen, Radius, Kyowa Kirin, Angitia, and Ascendis, and has been a speaker for Amgen, Radius, Ascendis, and Kyowa Kirin.
Elizabeth McAninch, MD, serves as a consultant for Acella Pharmaceuticals and AbbVie Inc. She is a co-founder of Equilibrate Therapeutics LLC.

Hans K. Ghayee, DO, serves as a consultant for Corcept.

John D. Carmichael, MD, has served as an advisory board member for Camurus, Novo Nordisk, Recordati, and Xeris. He is also a member of the American Association of Clinical Endocrinologists (Pituitary, Adrenal, Gonad, and Neuroendocrine Disease State Network) and the Pituitary Society.

Kaniksha Desai, MD, is a member of American Thyroid Association and is on the annual program committee. She is a member of the American Association of Clinical Endocrinologists and the Thyroid Disease State Network. She is a host on “The Thyroid Stimulating Podcast” on Medscape.

Marie E. McDonnell, MD, has served as a trial event adjudicator for a trial conducted by Eisai and receives research funding from Lilly, Inc, that is paid to her institution.

Sangeeta R. Kashyap, MD, has served as a consultant and coinvestigator to GI Dynamics; she has received research support from Fractyl, Inc; and she is chief medical officer of Gila Therapeutics.

Stephanie Page, MD, PhD, is an editor at UpToDate and has served as a consultant for Pharmajor International.

The following faculty reported no relevant financial relationships: Margaret Flynn Lippincott, MD

The medical editor for this activity reported no relevant financial relationships: Abbie L. Young, MS, CGC, ELS(D)

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
The activity is not supported by educational grant(s) or other funds from any commercial supporters.  

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By